Egolix 150 mg (Tablet)
Unit Price: ৳ 170.00 (1 x 10: ৳ 1,700.00)
Strip Price: ৳ 1,700.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Elagolix sodium |
| Company | Acme laboratories ltd |
| Also available as |
Indications
- Management of moderate to severe pain associated with endometriosis
Pharmacology
- GnRH receptor antagonist
- Inhibition of endogenous GnRH signaling
- Competitive binding to GnRH receptors
- Suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
- Decreased blood concentrations of estradiol and progesterone
Dosage & Administration
- Exclusion of pregnancy before starting treatment
- Start within 7 days from the onset of menses
- Initial treatment with 150 mg once daily up to 24 months
- Initial treatment with 200 mg twice daily up to 6 months
- Maximum 6 months usage in moderate hepatic impairment
- Caution in moderate to severe hepatic impairment
- Unevaluated in children and adolescents
Interaction
- Potentiation of P-gp substrates
- Limitation of doses for CYP2C19 substrates
- Antagonism of CYP3A substrates
- Antagonism of oral midazolam and rosuvastatin
- Consideration for increasing doses of antagonized drugs
- Reduced efficacy with estrogen-containing contraceptives
- No known food interaction
Contraindications
- Pregnancy
- Known osteoporosis
- Severe hepatic impairment
- Concomitant use of strong OATP1B1 inhibitors
Side Effects
- Common: hot flushes, night sweats, headache, nausea, amenorrhea, arthralgia, mood changes, bone loss
- Rare: insomnia, anxiety, elevated hepatic transaminase
Pregnancy & Lactation
- Insufficient human data on use in pregnant women
- Risk of early pregnancy loss
- Discontinuation if pregnancy occurs during treatment
- No information on effects on breastfed children or milk production
Precautions & Warnings
- Dose and duration-dependent decreases in bone mineral density
- Reduced ability to recognize pregnancy
- Suicidal ideation and mood disorders
- Elevations in serum alanine aminotransferase (ALT)
- Potential for reduced efficacy with estrogen-containing contraceptives
Use in Special Populations
- No dose adjustment in women with renal impairment or end-stage renal disease
- No dosage adjustment in women with mild hepatic impairment
- Safety and effectiveness not established in patients less than 18 years of age
Overdose Effects
- Monitoring for signs or symptoms of adverse reactions
- Initiation of appropriate symptomatic treatment
Therapeutic Class
- Gonadotropin-releasing hormone (GnRH) antagonist
Storage Conditions
- Cool, dry place
- Protection from light and moisture
- Keep out of reach of children